Stocks to Buy or Sell. In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands against other stocks to buy and sell highlighted in Jim Cramer’s latest calls. Jim Cramer in a latest program on CNBC reminded

Trump added Denmark to his growing list of tariff targets — including Canada, Mexico and China — as he has increasingly spoken of the U.S. taking Greenland off Denmark’s hands. Danish multinational pharmaceutical giant Novo Nordisk is the sole owner ...

Danish businesses are concerned about a possible trade conflict with the United States over Greenland, a major lobby group said on Thursday after business leaders, including CEO of obesity drugmaker Novo Nordisk,

A new weight loss drug from Novo Nordisk helped patients lose a large amount of weight, providing a boost for Novo in the competitive field.

Novo Nordisk's U.S.-listed shares are surging 9% Friday morning after the Danish drugmaker reported early stage results for its amycretin weight-loss drug.

It's a big week ahead as the U.S. Federal Reserve, European Central Bank and Bank of Canada hold their first meetings of 2025. Into the mix go earnings from heavyweights including Apple and Tesla, and likely market spikes from comments by new U.

Obesity drugs - especially Novo Nordic's Ozempic - dominated healthcare headlines in 2024, but Matt Miskin of John Hancock Investment Management told Reuters there are lots of competitors bringing out innovative new drugs - and he believes the sector is a healthy bet for investors trying to move away from Big Tech.

Shares were mixed in thin Asian trading on Monday after U.S. stocks edged back from their all-time high. Oil prices fell and U.S. futures sank, while Chinese shares shed some of

The Biotechnology Market report delivers crucial insights into the market's growth trajectory and the primary revenue drivers anticipated between 2025 and 2034. As industries undergo transformation and consumer preferences evolve,

Mads Krogsgaard Thomsen, CEO of Novo Nordisk Foundation, discusses European competitiveness.

European shares held steady with slight gains in financials and healthcare despite global uncertainties over U.S. President Donald Trump's proposed tariffs. The market's cautious optimism was challenged by pressure on automakers and basic resources.